AshwinPatkarMDMRCPsych, DFASAM

PubMed

• 58 citations
  CHANGES IN PLASMA NORADRENALINE AND SEROTONIN LEVELS AND CRAVING DURING ALCOHOL WITHDRAWAL
  Ashwin A. Patkar, Raman Gopalakrishnan, Prakash C. Naik, Heather W. Murray, Michael J. Vergare
  Alcohol and Alcoholism. 2003-05-01
• 18 citations
  Differences in Peripheral Noradrenergic Function among Actively Drinking and Abstinent Alcohol-dependent Individuals
  Ashwin A. Patkar, Charles A. Marsden, Prakash C. Naik, David A. Kendall, Raman Gopalakrishnan
  The American Journal on Addictions. 2004-05-06
• 14 citations
  Measurement-based treatment of residual symptoms using clinically useful depression outcome scale: Korean validation study
  Sang Won Jeon, Changsu Han, Young Hoon Ko, Seo Young Yoon, Chi-Un Pae
  Clinical Psychopharmacology and Neuroscience. 2017-02-28

Journal Articles

• Vitamin D deficiency and psychiatric illness  
  Harris HW, Jaiswal P, Holmes V, Weisler RH, Patkar AA, Current Psychiatry, 1/1/2013
• Case-control association study of 14 variants of CREB1, CREBBP and CREM on diagnosis and treatment outcome in major depressive disorder and bipolar disorder  
  Crisafulli C, Shim DS, Andrisano C, Pae CU, Chiesa A, Han C, Patkar AA, Lee SJ, Serretti A, De Ronchi D, Psychiatry Res, 1/2/2012
• A review of clinical trial data and clinical implications  
  Wang SM, Han C, Lee SJ, Patkar AA, Pae CU, Fleischhacker WW Paliperidone, Clin Drug Investig, 1/1/2012
• DAOA variants on diagnosis and response to treatment in patients with major depressive disorder and bipolar disorder  
  Chiesa A, Pae CU, Procelli S, Han C, Lee SJ, Patkar AA, Park MH, Jun TY, Serretti A, J Int Med Res, 1/1/2012
• Predictors of Response to Ziprasidone: Results from a 6-Week Randomized Double-Blind, Placebo-Controlled Trial for Acute depressive Mixed State  
  Pae CU, Patkar AA, Gilmer W, Holtzman N, Thommi SB, Ghaemi SN, Pharmacopsychiatry, 1/1/2012
• The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal  
  Mannelli P, Peindl K, Wu LT, Patkar AA, Gorelick DA, AM J Drug Alcohol Abuse, 1/1/2012
• An integrated alcohol abuse and medical treatment model for patients with hepatitis C  
  Proeschold-Bell RJ, Patkar AA, Naggie S, Coward L, Mannelli P, Yao J, Bixby P, Muir AJ, Dig Dis Sci, 1/1/2012
• Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variations rs10042486 on schizophrenia and response to antipsychotics  
  Crisafulli C, Chiesa A, Han C, Lee SJ, Park MH, Balzarro B, Andrisano C, Patkar AA, Pae CU, Serretti A, Eur Arch Psychiatry Clin Neurosci, 1/1/2012
• Influence of BDNF cariants on diagnosis and response to treatment in patients with major depression, bipolar disorder and schizophrenia  
  Pae CU, Chiesa A, Porcelli S, Han C, Patkar AA, Lee SJ, Park MH, Serretti A, De Ronchi D, Neuropsychobiology, 1/1/2012
• Influence of GRIA1, GRIA2, and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder  
  Chiesa A, Crisafulli C, Porcelli S, Han C, Patkar AA, Lee SJ, Park MH, Jun TY, Serretti A, Pae CU, Eur Arch Psychiatry Clin Neurosci, 1/5/2011
• Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study  
  Kane JM, D'Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RS, Clin Psychiatry, 1/1/2010
• HIV risk behavior in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study  
  Meade CS, Weiss RD, Fitzmaurice GM, Poole SA, Subramaniam GA, Patkar AA, Connery HS, Woody GE, Acquir Immune Defic Syndr, 1/1/2010
• Paroxetine mesylate: comparable to paroxetine hydrochloride? Expert Opin Pharmacother  
  Pae CU, Misra A, Ham BJ, Han C, Patkar AA, Masand PS, Expert Opin Pharmacother, 1/1/2010
• Diagnosis and Treatment of Opioid Dependence  
  Patkar AA, Bhatia K, Lee J, BMJ Point of Care, 1/1/2009
• Psychometric properties of the patient Health Questionnaire- 15 (PHQ-15) for measuring the somatic symptoms of psychiatric outpatients  
  Han C, Pae CU, Patkar AA, Masand PS, Kim KW, Joe SH, Jung IK, Psychosomatics, 1/1/2009
• Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain  
  Langley PC, Patkar AA, Boswell KA, Benson CJ, Schein JR, Curr Med Res Opin, 1/1/2009
• Opioid use affects antioxidant activity and purine metabolism: preliminary results  
  Mannelli P, Patkar AA, Rozen S, Matson W, Krishnan R, Kaddurah-Daouk R, Human Psychopharmacology, 1/1/2009
• Methylphenidate extended release (OROS MPH) for the treatment of antidepressant- related sexual dysfunction in patients with treatment-resistant depression: results fr...  
  Pae CU, Marks DM, Masand PS, Peindl K, Hooper-Wood C, Han C, Mannelli P, Ciccone P, Patkar AA, Clin Neuropharmacol, 1/1/2009
• History of early abuse as a predictor of treatment response in patients with fibromyalgia: post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled...  
  Pae CU, Masand PS, Marks DM, Krulewicz S, Han C, Peindl K, Mannelli P, Patkar AA, World J Biol Psychiatry, 1/1/2009
• Short-, intermediate-, and long-term outcomes of Pennsylvania's continuum of tobacco education pilot project  
  Leone FT, Evers-Casey S, Veloski J, Patkar AA, Kanzleiter L, Pennsylvania continuum of tobacco education work shop, Nicotine and Tobacco Research, 1/1/2009
• A randomized, double-blind, placebo-controlled trial of controlled release paroxetine in Irritable Bowel Syndrome  
  Masand PS, Pae CU, Krulewicz S, Peindl K, Mannelli P, Varia I, Patkar AA, Psychosomatic Medicine, 1/1/2009
• Infrequent illicit methadone use among stimulant- using patients in methadone maintenance treatment programs: a national drug abuse treatment clinical trials network  
  Wu LT, Blazer DG, Stitzer ML, Patkar AA, Blaine JD, Am J Addict, 1/1/2008
• A case of transient hallucination with ropinirole augmentation in a patient with treatment-resistant depression: is there differential effect of ropinirole dose on dev...  
  Pae CU, Marks DM , Han C, Patkar AA, Progress in Neuropsychopharmacology and Biological Psychiatry, 1/1/2008
• Delirium: Underrecognized and Undertreated  
  Pae CU, Marks DM, Han C, Patkar AA, Masand P, Curr Treat Options Neurol, 1/1/2008
• The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double- blind, placebo-control...  
  Pae CU, Lim HK, Peindl K, Ajwani N, Serretti A, Patkar AA, Lee C, Int Clin Psychopharmacol, 1/1/2008
• Join now to see all

Books/Book Chapters

• Interventions for Addiction: Comprehensive Addictive Behaviors and Disorders 
  Chapter: Medication for Cravings in Substance Use Disorders 
  Page 527 - 542Patkar, A.A., Lee, J.C., Burgess, D.M.Editors: Miller P.Elsevier Inc., Academic Press, San Diego, CA2013
• Guide to Assessment Scales in Schizophrenia 
  Chapter: Rating Scales for Substance Abuse 
  Page 181 - 187Patkar AA & Lee JCEditors: Keefe R.Springer Health Care, New York, NY2012
• Pharmacology and Therapeutics. From Principles to Practice 
  Chapter: Neuropharmacology of Anxiety Disorders 
  Pae Chi-un and Patkar AAEditors: Waldman SA and Terzic A.Elsevier, New York, NY2008
• Textbook of Consultation-Liaison Psychiatry 
  Chapter: Mania, Catatonia, & Psychosis in the Medically Ill 
  Masand PS, Christopher E, Clary GS, Mago RM, Patkar AAAmerican Psychiatric Press, Washington, DC2004
• Join now to see all

Abstracts/Posters

• Serotonin transporter gene polymorphisms in cocaine dependence
  ll KP, Patkar AA, Berrettini WH, Gottheil E, Wendel B, Sterling RC and Weinstein SP, AMIS-PHL Student Poster Competition, Philadelphia, PA, 1/1/1999

Lectures

• Urinary concentrations of buprenorphine and norbuprenorphine as indicators of noncompliance and diversion. 
  Austin, TX - 1/23/2015
• Brain Music Therapy for insomnia and anxiety in Addiction Treatment. 
  Austin, TX - 1/23/2015
• Screening and Brief Intervention for substance abuse in patients with Hepatitis C. 
  Duke University Health Center - 1/18/2015
• Strategies for treatment of opioid addiction. 
  Raleigh, NC - 1/17/2015
• Resilience and Recovery in Substance Abuse Treatment. 
  Point Clear, AL - 1/15/2015
• Screening and Brief Intervention training for students and Professionals. 
  Southern Heath Area Education Center, Fayetteville, NC - 1/13/2015
• Early Improvement with augmentation for major depressive disorder: A fresh look at the evidence. 
  Qingdao, China - 1/25/2014
• Management of psychiatric comorbidity in substance use disorders. 
  Asheville, NC - 1/22/2014
• An integrated framework to managing chronic pain, mental illness and substance abuse. 
  Raleigh, NC - 1/17/2014
• Substance use disorders in DSM-5. Revisions and Rationale 
  Pune, India - 1/16/2014
• Effects of milnacipran on pain and sexual function and in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial. 
  Hollywood, FL - 1/16/2014
• Project Lazarus: Chronic pain initiative in North Carolina 
  Wilmington, NC, 2013; Durham, NC, 2014; Henderson, NC, 2014 - 1/14/2014
• Effects of milnacipran on neurocognition and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial. 
  New York, NY - 1/3/2014
• F-MRI changes in a randomized controlled trial of ondansetron-methylphenidate combination in stimulant dependence. 
  New York, NY - 1/3/2014
• Early improvement with vilazodone in adults with major depressive disorder. A post-hoc analysis of a randomized, double-blind, placebo-controlled trial. 
  New York, NY - 1/3/2014
• Three Different Dose Initiation Strategies With Vilazodone In Major Depressive Disorder: A 8-Week Randomized, Double-Blind Trial Comparing Safety And Tolerability Of S... 
  New York, NY - 1/3/2014
• Lisdexamphetamine dimesylate augmentation in major depressive disorder: Post hoc item analysis of residual symptoms on the QIDS-SR in clinician rated remitters and non... 
  Hollywood, FL - 1/28/2013
• Milnacipran, neurocognition and fatigue in fibromyalgia: A double blind, randomized 13-week crossover trial. 
  San Francisco, CA - 1/18/2013
• Posthoc analysis of lisdexamphetamine dimesylate augmentation therapy effects on sleep related endpoints in adults with major depressive disorder. 
  San Francisco, CA - 1/18/2013
• Lisdexamphetamine dimesylate augmentation in anxious or nonanxious major depressive disorder. 
  San Francisco, CA - 1/18/2013
• Lisdexamphetamine dimesylate augmentation effects on executive function in major depressive disorder based on level of executive function impairment. 
  San Francisco, CA - 1/16/2013
• Screening and Brief Interventions for Substance Abuse 
  Multiple Locations, 2011, 2013 - 1/12/2013
• Mitigating Misuse and Abuse of Prescription Stimulants 
  Asheville, NC - 1/12/2013
• Chronic pain initiative in North Carolina 
  Gastonia, NC - 1/10/2013
• A proof-of-concept bench-to-bedside project. 
  Seoul, Republic of Korea - 1/6/2013
• Join now to see all

Other

• Opioid Use disorder 
  Patkar, A.A., Lee, J.C., Burgess, D.M., Disease State Management. Epocrates online. Athena Health, BMJ Publishing group
  London, United Kingdom - 1/1/2012